Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab

NCT00226200 is registered in ClinicalTrials.gov with University of Mississippi Medical Center as lead sponsor.

NCT NCT00226200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00226200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Soluble CD23 Expression as a Marker of Immunomodulation and CLinical Response in Asthma Patients Treated With Omalizumab
Lead sponsor
University of Mississippi Medical Center
Phase
Not applicable
Overall status
Terminated
Start date
November 30, 2004
Completion date
October 31, 2007
Enrollment
80
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma